ID W5LL45_ASTMX Unreviewed; 985 AA.
AC W5LL45;
DT 16-APR-2014, integrated into UniProtKB/TrEMBL.
DT 05-DEC-2018, sequence version 2.
DT 27-MAR-2024, entry version 50.
DE RecName: Full=Myomesin 3 {ECO:0008006|Google:ProtNLM};
OS Astyanax mexicanus (Blind cave fish) (Astyanax fasciatus mexicanus).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Characiformes;
OC Characoidei; Characidae; Astyanax.
OX NCBI_TaxID=7994 {ECO:0000313|Ensembl:ENSAMXP00000020557.2, ECO:0000313|Proteomes:UP000018467};
RN [1] {ECO:0000313|Proteomes:UP000018467}
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=female {ECO:0000313|Proteomes:UP000018467};
RA Jeffery W., Warren W., Wilson R.K.;
RL Submitted (MAR-2013) to the EMBL/GenBank/DDBJ databases.
RN [2] {ECO:0000313|Proteomes:UP000018467}
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=female {ECO:0000313|Proteomes:UP000018467};
RX PubMed=25329095; DOI=10.1038/ncomms6307;
RA McGaugh S.E., Gross J.B., Aken B., Blin M., Borowsky R., Chalopin D.,
RA Hinaux H., Jeffery W.R., Keene A., Ma L., Minx P., Murphy D., O'Quin K.E.,
RA Retaux S., Rohner N., Searle S.M., Stahl B.A., Tabin C., Volff J.N.,
RA Yoshizawa M., Warren W.C.;
RT "The cavefish genome reveals candidate genes for eye loss.";
RL Nat. Commun. 5:5307-5307(2014).
RN [3] {ECO:0000313|Ensembl:ENSAMXP00000020557.2}
RP IDENTIFICATION.
RG Ensembl;
RL Submitted (NOV-2023) to UniProtKB.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR AlphaFoldDB; W5LL45; -.
DR Ensembl; ENSAMXT00000020557.2; ENSAMXP00000020557.2; ENSAMXG00000019930.2.
DR eggNOG; ENOG502RDUJ; Eukaryota.
DR GeneTree; ENSGT00940000158669; -.
DR HOGENOM; CLU_004753_1_0_1; -.
DR Proteomes; UP000018467; Unassembled WGS sequence.
DR Bgee; ENSAMXG00000019930; Expressed in muscle tissue and 7 other cell types or tissues.
DR CDD; cd00063; FN3; 4.
DR Gene3D; 2.60.40.10; Immunoglobulins; 8.
DR InterPro; IPR003961; FN3_dom.
DR InterPro; IPR036116; FN3_sf.
DR InterPro; IPR007110; Ig-like_dom.
DR InterPro; IPR036179; Ig-like_dom_sf.
DR InterPro; IPR013783; Ig-like_fold.
DR InterPro; IPR013098; Ig_I-set.
DR InterPro; IPR003599; Ig_sub.
DR InterPro; IPR003598; Ig_sub2.
DR PANTHER; PTHR14340:SF24; -; 1.
DR PANTHER; PTHR14340; MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 3; 1.
DR Pfam; PF00041; fn3; 4.
DR Pfam; PF07679; I-set; 2.
DR PRINTS; PR00014; FNTYPEIII.
DR SMART; SM00060; FN3; 4.
DR SMART; SM00409; IG; 3.
DR SMART; SM00408; IGc2; 2.
DR SUPFAM; SSF49265; Fibronectin type III; 3.
DR SUPFAM; SSF48726; Immunoglobulin; 3.
DR PROSITE; PS50853; FN3; 4.
DR PROSITE; PS50835; IG_LIKE; 3.
PE 4: Predicted;
KW Immunoglobulin domain {ECO:0000256|ARBA:ARBA00023319};
KW Reference proteome {ECO:0000313|Proteomes:UP000018467};
KW Repeat {ECO:0000256|ARBA:ARBA00022737}.
FT DOMAIN 80..175
FT /note="Ig-like"
FT /evidence="ECO:0000259|PROSITE:PS50835"
FT DOMAIN 189..284
FT /note="Fibronectin type-III"
FT /evidence="ECO:0000259|PROSITE:PS50853"
FT DOMAIN 347..440
FT /note="Fibronectin type-III"
FT /evidence="ECO:0000259|PROSITE:PS50853"
FT DOMAIN 446..540
FT /note="Fibronectin type-III"
FT /evidence="ECO:0000259|PROSITE:PS50853"
FT DOMAIN 548..648
FT /note="Fibronectin type-III"
FT /evidence="ECO:0000259|PROSITE:PS50853"
FT DOMAIN 634..733
FT /note="Ig-like"
FT /evidence="ECO:0000259|PROSITE:PS50835"
FT DOMAIN 876..965
FT /note="Ig-like"
FT /evidence="ECO:0000259|PROSITE:PS50835"
FT REGION 630..649
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ SEQUENCE 985 AA; 110185 MW; 40B5B0D8B85A1124 CRC64;
MADDELRQRD KWTLFGNEAE KVEIGVIRNQ HAERKCSLQL KFLEDLSRKE PDFPVPLRPH
TVWEGMAVKL SCTVQGCPAP QTEALFDSTF PPSFVKEGET LVLSCGFTSP LLPFQQDVSW
FRDGEPLRPS GRVEVQTALR SSTLTLRGAH KEHEGFYSTR LQTRDGPQEH SAFIYIRDGA
AAVVGAAGSP LQVECSDVNR DYVFLSWKPP SADGAAPVQG YYIERCEVGL LKWSRCNEVV
QKVCYYPVMG LQENTMYQFR VCAVNQAGVG RPSKPTEPIL TSDPMEPSRT MGNVSIAGKN
SWHLASMDMT VQSTRFAAFD LQKGKSYCFR VRSINNQHLE NICVPAAPHC IQAVADTDSS
AVLLWKEPKN TEGILGYYLY CSEVGTSNWR TINNKPVNGT RFTVHGLNTN KDYVFRVKSV
GRAGNSHYSE ESQPVRIKAA KVVPSPPSGV CLLHCSGSEM VIGWRAPANQ GGEAVKGYFL
DQREKPQTVW REVNPKPVKE RVYKVSALLE GHYYQFRLFA SNVIGLSKPS QPSEAFLCEP
WTMPEPGCPY DLELREVRRE SLVVMWAEPL YQGQSQITGY VVEISQGEES EDWTEVTQES
TMKNHIKNHI SGLRAGQTYR LRVSAVNSAG VGRPSLPTEP ITAQTKPGTK DMEIGVDNDG
FIFLSFQASE TAEDGQFKWN KNYRETIDAG RAHLETKHKT SVLTFTAASE EDLGLYTAEM
MDSPGVSSSY NFTARKINFD KPNGLVEILF DQLSKEDEGS YTAQLKDGRA KNQFTLVLVD
ESRKEAGVYR AVVSDSRGED ESILELVDTE KKMDQGERNA PGSSMQKVWN EIFNPTENDK
GKYTLEMFDG QETHKRHLDL SGQGTAFCQC FFLDRAKVTK GLPDVVAIME GKSLCLTCFA
DGDPAPEMFW LKNDREITST GQYHIAHENK CTTITISSVT MEDSGNYSIF VRNSYGSQTV
HVTVSVYKHG EKPRAVKKKY FFLLV
//
